Introduction: In neuroendocrine tumors (NETs), the workup is often difficult not only to visualize but also to co-localize the lesions anatomically. Liver and bones are one of the most frequent sites of metastases in patients with endocrine tumors. The Tyr3-octreotate (TATE) somatostatin analogue differs from TOC in that the terminal threonine replaces threoninol. The terminal threonine results in a higher receptor binding (mainly subtype 2) and better internalisation, with the consequence that tumor uptake of the tracer is intense.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: MD, PhD Norbert Szalus